AGIO News and Press, Agios Pharmaceuticals Inc. From 02/12/26

2026-02-12 06:33:29 ET More on Agios Pharmaceuticals Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Agios...

PYRUKYND ® (mitapivat) worldwide net revenues of $20.0 million in fourth quarter and $54.0 million for full year AQVESME™ (mitapivat) for thalassemia now available in U.S. following FDA approval Company will have pre-sNDA meeting with FDA for mitapivat in sickle cell disease in f...

Baxter International Inc. (BAX) is expected to report $0.53 for Q4 2025 Nova Ltd. (NVMI) is expected to report $1.94 for Q4 2025 West Pharmaceutical Services Inc. (WST) is expected to report $1.83 for Q4 2025 Universal Logistics Holdings Inc. (ULH) is expected to report $-0.05 for Q4 ...

2026-02-11 13:22:59 ET More on Agios Pharmaceuticals Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Agios...

CAMBRIDGE, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thur...

2026-01-14 14:36:03 ET Agios Pharmaceuticals, Inc. (AGIO) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 11:15 AM EST... Read the full article on Seeking Alpha For further details see: Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Hea...

AQVESME™ (mitapivat) U.S. commercial launch in thalassemia underway following December 2025 FDA approval Pre-sNDA meeting with FDA for mitapivat in sickle cell disease anticipated in first quarter of 2026, with planned U.S. regulatory submission to follow Company progressing early- and...

CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that its management team is scheduled to present at the 44 th A...

2025-12-26 08:15:02 ET Citigroup analyst issues BUY recommendation for AGIO on December 26, 2025 01:27PM ET. The previous analyst recommendation was Buy. AGIO was trading at $29.17 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current a...

2025-12-26 07:05:46 ET from Leerink Partners issued a price target of $40.00 for AGIO on 2025-12-26 11:26:49. The adjusted price target was set to $40.00. At the time of the announcement, AGIO was trading at $29.17. The overall price target consensus is at $39.75 with hi...